Genentech is very excited to kick off #MSVisibility 2022 this coming Monday, March 28th with the launch of a new, bilingual video, focusing [...]
Preclinical findings showed that tolebrutinib, among the investigational BTK inhibitors tested, had the best combination of brain [...]
Researchers from Harvard University recently found that the Epstein-Barr virus (EBV), which is most known for leading to mononucleosis, is [...]
#MSVisibility Virtual Concert Thank you for your interest in the first-ever #MSVisibility Virtual Concert, a free event to celebrate and [...]
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a monotherapy in Parts 1 and 2, to determine the [...]
